Perceptive Advisors - EIGER BIOPHARMACEUTICALS INC ownership

EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 43 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
Perceptive Advisors ownership history of EIGER BIOPHARMACEUTICALS INC
ValueSharesWeighting
Q4 2021$1,452,000
+55.5%
279,780
+100.0%
0.01%
-21.4%
Q3 2021$934,000
-60.8%
139,890
-50.0%
0.01%
-6.7%
Q2 2021$2,384,000
+92.6%
279,780
+100.0%
0.02%
-6.2%
Q1 2021$1,238,000
-28.0%
139,8900.0%0.02%
-11.1%
Q4 2020$1,719,000
+51.1%
139,8900.0%0.02%
+5.9%
Q3 2020$1,138,000
-15.3%
139,8900.0%0.02%
-22.7%
Q2 2020$1,343,000
+41.2%
139,8900.0%0.02%
-12.0%
Q1 2020$951,000
-54.4%
139,8900.0%0.02%
-39.0%
Q4 2019$2,084,000
+45.4%
139,8900.0%0.04%
+5.1%
Q3 2019$1,433,000
-3.3%
139,8900.0%0.04%
+14.7%
Q2 2019$1,482,000
-24.2%
139,8900.0%0.03%
-38.2%
Q1 2019$1,955,000
+37.6%
139,8900.0%0.06%
+1.9%
Q4 2018$1,421,000
-24.9%
139,890
-11.3%
0.05%
+5.9%
Q3 2018$1,892,000
-1.6%
157,6790.0%0.05%
+2.0%
Q2 2018$1,923,000
+23.8%
157,6790.0%0.05%
+16.3%
Q1 2018$1,553,000
-29.4%
157,6790.0%0.04%
-41.1%
Q4 2017$2,199,000
-36.6%
157,679
-50.0%
0.07%
+10.6%
Q3 2017$3,468,000
+178.6%
315,358
+100.0%
0.07%
+4.8%
Q2 2017$1,245,000
-31.0%
157,6790.0%0.06%
-38.8%
Q1 2017$1,805,000
-1.7%
157,6790.0%0.10%
-21.4%
Q4 2016$1,836,000
+5.6%
157,679
+21.4%
0.13%
+17.0%
Q3 2016$1,739,000
-16.4%
129,920
+23.8%
0.11%
-22.2%
Q2 2016$2,079,000
+18.2%
104,9200.0%0.14%
-6.5%
Q1 2016$1,759,000104,9200.15%
Other shareholders
EIGER BIOPHARMACEUTICALS INC shareholders Q1 2018
NameSharesValueWeighting ↓
P.A.W. CAPITAL CORP 540,000$4,482,0004.68%
Knoll Capital Management, LLC 694,232$5,762,0003.62%
Telemetry Investments, L.L.C. 213,000$1,768,0002.79%
ACT CAPITAL MANAGEMENT, LLC 250,000$2,075,0002.20%
VR Adviser, LLC 1,469,767$12,199,0001.98%
INTERWEST VENTURE MANAGEMENT CO 560,990$4,656,0001.78%
683 Capital Management, LLC 3,375,000$28,013,0001.50%
Trellus Management Company, LLC 300,000$2,490,0001.45%
Altium Capital Management LP 440,000$3,652,0001.22%
CAXTON CORP 116,884$970,0001.21%
View complete list of EIGER BIOPHARMACEUTICALS INC shareholders